CFF Awards $2.17M to Support Trial of Inhaled NO for NTM Lung Infections

CFF Awards $2.17M to Support Trial of Inhaled NO for NTM Lung Infections

287078

CFF Awards $2.17M to Support Trial of Inhaled NO for NTM Lung Infections

The Cystic Fibrosis Foundation (CFF) has given Beyond Air up to $2.17 million to test its portable inhaled nitric oxide therapy for people with cystic fibrosis (CF) who have chronic, treatment-resistant lung infections caused by non-tuberculous mycobacteria (NTM). This grant award will support a pilot clinical trial to determine the safety and effectiveness of the investigational therapy, LungFit GO (a nitric oxide generator and delivery system), used along with current treatments that include the antibiotics amikacin and azithromycin. NTM…

You must be logged in to read/download the full post.